Effervescent Tablet Market Report 2026

The effervescent tablet market size has grown rapidly in recent years. It will grow from $39.6 billion in 2025 to $43.83 billion in 2026 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to increasing prevalence of chronic diseases, rising consumer awareness about supplements, growth of the pharmaceutical sector, advancements in tablet formulation technologies, demand for convenient dosage forms.

The effervescent tablet market size is expected to see rapid growth in the next few years. It will grow to $66.3 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to expansion of personalized medicine, rising adoption of nutraceuticals, technological advancements in effervescent tablet delivery, growing geriatric population, increasing demand for pediatric formulations. Major trends in the forecast period include fast-dissolving formulations, personalized dosage solutions, functional & nutraceutical effervescent tablets, pediatric & geriatric focused tablets, enhanced flavor & consumer acceptability.

The growing geriatric population is anticipated to drive the expansion of the effervescent tablet market in the coming years. The geriatric population refers to the proportion of individuals aged 65 and above in comparison to the working-age population between 18 and 64 years. The increase in the elderly population presents a significant market opportunity for effervescent tablets, as they address the unique healthcare needs and preferences of this group through formulation benefits, ease of administration, and customization capabilities, making them a convenient and effective healthcare option. For example, in October 2025, the World Health Organization, a Switzerland-based international public health organization, reported in the WHO Ageing & Health fact sheet that by 2030, one in six people worldwide will be aged 60 years or older; by 2050, the population aged 60 and above is expected to double to 2.1 billion, while those aged 80 and above are projected to triple to 426 million. Therefore, the rise in the geriatric population is fueling the growth of the effervescent tablet market.

Leading companies in the effervescent tablet market are concentrating on developing innovations such as liposomal glutathione effervescent tablets to improve bioavailability, enhance antioxidant delivery, and meet the increasing consumer demand for convenient and effective health supplements. Liposomal glutathione effervescent tablets integrate advanced absorption technology with antioxidant benefits, providing a practical and efficient solution to support immune function, detoxification, and overall well-being. For example, in August 2024, INJA Wellness, a US-based company specializing in wellness products and health-promoting supplements, launched liposomal glutathione effervescent tablets. These tablets employ advanced liposomal technology to improve the absorption of glutathione, a potent antioxidant, and are formulated to dissolve in water for ease of consumption while supporting immune health.

In February 2024, EffRx Pharmaceuticals SA, a Switzerland-based pharmaceutical company specializing in effervescent tablets, entered into a partnership with Lupin Limited. Through this collaboration, EffRx Pharmaceuticals SA aims to commercialize BINOSTO (alendronate 70 mg effervescent tablets) in Vietnam and the Philippines via Lupin. BINOSTO is primarily used for the treatment of postmenopausal osteoporosis in women. Lupin Limited is an India-based pharmaceutical company.

Major companies operating in the effervescent tablet market are Bayer AG, Hermes Arzneimittel GmbH, GlaxoSmithKline PLC, Reckitt Benckiser Group PLC, Bristol-Myers Squibb Company, Bliss GVS Pharma Limited, Herbalife International Inc., Amerilab Technologies Inc., Pfizer Inc., Novartis AG, Perrigo Company PLC, Chiesi Farmaceutici SpA, SG Biopharm Pvt. Ltd., Tower Laboratories Ltd., American Health, By-health Co. Ltd., Vitabiotics Ltd., Prestige Brands Inc., Nuun and Company Inc., Amway Corp, GNC Holdings Inc., Sanofi SA, Merck KGaA, Roche Holding AG, Johnson & Johnson, Nestle SA, Dr Reddy's Laboratories Ltd.

North America was the largest region in the effervescent tablets market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the effervescent tablet market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the effervescent tablet market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the effervescent tablet market by increasing the cost of imported raw materials such as active pharmaceutical ingredients and excipients. This has impacted pharmaceutical manufacturers and dietary supplement producers, particularly in regions dependent on imports from Asia and Europe. Segments like vitamin and mineral supplements and cold and flu remedies face higher production costs, while local manufacturers may gain competitive advantage. Overall, tariffs may encourage domestic production and sourcing diversification, but could slow global market expansion temporarily.

The effervescent tablet market research report is one of a series of new reports that provides effervescent tablet market statistics, including effervescent tablet industry global market size, regional shares, competitors with a effervescent tablet market share, detailed effervescent tablet market segments, market trends and opportunities, and any further data you may need to thrive in the effervescent tablet industry. This effervescent tablet market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Effervescent tablets are a solid tablet dosage form designed to dissolve rapidly upon contact with water by releasing carbon dioxide. These tablets completely disintegrate within a few minutes, allowing the medication to be released into a solution.

The primary products of effervescent tablets include medications and supplements. Medication refers to any drug, medical preparation, or therapeutic agent used to treat biological disorders and diseases. The manufacturing methods for effervescent tablets include dry processes and wet granulation, which are utilized for indications such as diuretics, pain management, gastric conditions, respiratory disorders, and others. They are used in dental products, dietary supplements, pharmaceuticals, and other applications by end users including hospitals, specialty clinics, home care settings, and others.

The effervescent tablet market consists of sales of prescription-based tablets and daily-used tablets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.